United Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $735,900 | $748,900 | $714,900 | $677,700 |
Gross Profit | 660,000 | 665,800 | 637,100 | 604,800 |
EBITDA | 424,100 | 417,800 | 338,600 | 426,900 |
EBIT | 404,400 | 398,700 | 319,900 | 411,900 |
Net Income | 301,300 | 309,100 | 278,100 | 306,600 |
Net Change In Cash | 735,900 | 748,900 | 714,900 | 677,700 |
Free Cash Flow | 254,500 | 300,700 | 187,100 | 338,300 |
Cash | 1,697,200 | 1,553,900 | 1,355,700 | 1,251,500 |
Basic Shares | 48,700 | 48,400 | 47,500 | 49,700 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $2,877,400 | $2,327,500 | $1,936,300 | $1,685,500 |
Gross Profit | 2,567,700 | 2,070,000 | 1,789,600 | 1,563,000 |
EBITDA | 1,654,400 | 1,386,800 | 1,040,300 | 736,800 |
EBIT | 1,581,900 | 1,333,600 | 989,000 | 686,900 |
Net Income | 1,195,100 | 984,800 | 727,300 | 475,800 |
Net Change In Cash | 2,877,400 | 2,327,500 | 1,936,300 | 1,685,500 |
Cost of Revenue | 66,400 | 156,100 | ||
Free Cash Flow | 1,080,600 | 747,600 | 663,700 | 477,400 |
Cash | 1,697,200 | 1,207,700 | 961,200 | 894,800 |
Basic Shares | 48,500 | 49,700 | 48,500 | 47,300 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | $6.19 |
2024-09-30 | $6.39 |
2024-06-30 | $5.85 |
2024-03-31 | $6.17 |
